Spruce Biosciences prices $69M public offering of common stock and pre-funded warrants

SPRUCE BIOSCIENCES, INC.

Gross proceeds ~$69M from 1.33M shares at $50/share and 50K pre-funded warrants at $49.99.
Underwriters' option for 180K additional shares exercised in full on April 21, 2026.
Offering expected to close April 22; net proceeds for working capital and general corporate purposes.
Pre-funded warrants exercisable immediately at $0.01 per share, with a 4.99% beneficial ownership cap.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. entered into Underwriting Agreement with Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. valued at $69.0 million (effective 2026-04-20).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc.
Value: $69.0 million
Effective: 2026-04-20

Exact text from the filing

On April 20, 2026, Spruce Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters listed therein

View on SEC.gov

76 material agreements filed in the last 30 days. Browse all material agreements →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-167332

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.